<DOC>
	<DOCNO>NCT00587873</DOCNO>
	<brief_summary>The objective study determine incidence complete partial response duration response patient recurrent resistant Hodgkin 's disease ( HD ) treat sequential administration oral 6-Thioguanin ( 6-TG ) IV Methotrexate ( MTX ) .</brief_summary>
	<brief_title>Sequential Administration Oral 6-Thioguanine ( 6-TG ) After Methotrexate ( MTX ) Patients With Relapsed Hodgkin 's Disease ( Phase II )</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients histologic proof HD relapse fail &gt; = 2 prior chemotherapy regimen . Patients must life expectancy least 8 week . All patient must ECOG performance level rating &lt; = 2 . Patients parent ( guardian ) must sign informed consent indicate aware investigational nature study . Patients must recover toxic effect prior therapy enter study least 2 week elapse since end last course CT . Patients must adequate liver function ( bilirubin &lt; = 2.0 mg/dl , SGOT le 1.5 time normal ( unless due disease ) , adequate renal function ( creatinine &lt; = 1.5 mg/dl , creatinine clearance &gt; = 60 ml/min/1.73 m2 ) . Patients granulocyte count &gt; = 500/gL platelet count &gt; = 100,000/uL ( unless due disease involvement bone marrow ) . Male female patient childbearing age use effective method contraception , sexually active . Patients active infection significant medical condition malignancy shall exclude . Patients HD prior MTX 6TG exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>6-Thioguanine</keyword>
	<keyword>94-030</keyword>
</DOC>